EGFR and cancer: Moreover, ΔNp63 also activated phospho-EGFR (Y1086); promoted EGF-mediated activation of ERK, Akt, and JNK signaling; stimulated cancer proliferation, motility, and invasion; and enhanced resistance to cisplatin-induced apoptosis; on the other hand, when a missense mutation was introduced into the ΔNp63 DBD at position 202, it will downregulate the expression of EGFR (109, 110).